2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Uniquely for a common cardiovascular disease, there are very few randomized, controlled, clinical trials in patients with HCM. For this reason, the majority of the recommendations in this document are based on observational cohort studies and expert consensus opinion. The aim is to provide healthcare professionals with a practical diagnostic and treatment framework for patients of all ages and, as the majority of patients have a genetic cause for their disease, the Guidelines also consider the implications of a diagnosis for families and provide specific advice on reproduction and contraception.
Adoption of a purely morphological disease definition means that the number of possible aetiologies is considerable, particularly in young children. As it is impractical to provide an exhaustive compendium of all possible causes of HCM, the Guidelines focus on the most common genetic and non-genetic subtypes, but additional references for less common disorders are provided. Similarly, treatment recommendations focus largely on generic management issues but make reference to rare diseases when appropriate.
Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.